PCMI
EBS icon

Paradigm Capital Management Inc’s Emergent Biosolutions EBS Stock Holding History

Paradigm Capital Management Inc’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,000
Closed -$210K – 145
2022
Q3 		$210K Hold
10,000
– – 0.02% 137
2022
Q2 		$310K Hold
10,000
– – 0.02% 136
2022
Q1 		$411K Sell
10,000
-55,289
-85% -$2.44M 0.02% 136
2021
Q4 		$2.84M Buy
+65,289
New +$2.95M 0.13% 94

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Paradigm Capital Management Inc's EBS Position: Q4 2022 in Review

Paradigm Capital Management Inc sold out of Emergent Biosolutions (EBS) in Q4 2022, closing a stake of 10,000 shares — an estimated $210K sold.

Paradigm Capital Management Inc first reported a position in EBS in Q4 2021 and held it in 4 quarters. The position peaked at $2.84M in Q4 2021. 198 funds tracked by Wall St. Rank hold EBS as of Q4 2022.

  • Paradigm Capital Management Inc reported no remaining Emergent Biosolutions position as of Q4 2022 after selling out during the quarter.
  • Paradigm Capital Management Inc sold 10,000 Emergent Biosolutions shares in Q4 2022, an estimated $210K.
  • Paradigm Capital Management Inc first reported a position in Emergent Biosolutions in Q4 2021 and held it in 4 quarters.
  • Paradigm Capital Management Inc's Emergent Biosolutions position peaked at $2.84M in Q4 2021.
  • 198 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2022.

Based on Paradigm Capital Management Inc's 13F filing for Q4 2022, filed 3 Feb 2023.